BioCentury | May 11, 2018
Clinical News

Medigene reports Phase I/II data for prostate cancer vaccine

...with human telomerase reverse transcriptase (TERT) and survivin (BIRC5). Medigene AG (Xetra:MDG1), Martinsried, Germany Product: DC vaccine targeting PSA... in high-risk prostate cancer patients Endpoint: NA Status: Phase I/II data Milestone: NA Jaime De Leon DC vaccine targeting PSA American...
Items per page:
1 - 1 of 1